Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31168473 | 0.75 | CYP1A2 (0.44) | DYRK1AKMT2AIRAK4ALDH1A1MAPT | |
| SCHEMBL827713 | 0.75 | CYP1A2 (0.44) | DYRK1AKMT2AIRAK4ALDH1A1MAPT | |
| SCHEMBL13459982 | 0.75 | DYRK1A (0.40) | DYRK1AKMT2AIRAK4ALDH1A1MAPT | |
| SCHEMBL1269987 | 0.75 | FTO (0.40) | DYRK1AHTTIRAK4ALDH1A1MAPT | |
| SCHEMBL31168602 | 0.75 | TRPA1 (0.34) | DYRK1AIRAK4PDE4BPDE4DPDE4A | |
| SCHEMBL15651507 | 0.71 | CYP2A6 (0.46) | DYRK1APDE4BPDE4DPDE4A | |
| SCHEMBL12814747 | 0.71 | KDM4E (0.45) | HTTKMT2AALDH1A1MAPTNPSR1 | |
| SCHEMBL3802865 | 0.71 | RECQL (0.36) | DYRK1APDE4BPDE4D | |
| SCHEMBL8122154 | 0.71 | CYP2A6 (0.46) | HTTIRAK4ALDH1A1 | |
| SCHEMBL12458419 | 0.71 | IRAK4 (0.32) | DYRK1AIRAK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024217519-A1 | PYRROLE SULFONYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 天地恒一制药股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| US-20230192617-A1 | AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2023-06-22 | — | — | US | disclosed |
| EP-4153566-A1 | AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer CropScience Aktiengesellschaft (DE) | 2023-03-29 | — | — | EP | disclosed |
| CN-115803317-A | Azabicyclo (thio) amides as fungicidal compounds | 拜耳作物科学股份公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022129913-A1 | ALKYNE DERIVATIVES AS INHIBITORS OF C-ABL | BENEVOLENTAI BIO LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021233861-A1 | AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-11-25 | — | — | WO | disclosed |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-22 | — | — | US | disclosed |
| CN-112312908-A | OGA inhibitor compounds | 詹森药业有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2613781-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| US-7332504-B2 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332504-B2 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2008-02-19 | — | — | US | disclosed |
| WO-2007039146-A1 | 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-6833370-B1 | Selectively controlling neurotransmitter release; such as n-((3)-1-(6-chloro-3-pyridinyl)pyrrolidinyl)-n-methylamine | ABBOTT LABORATORIES | 2004-12-21 | — | — | US | disclosed |
| EP-1428824-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1178982-A1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LABORATORIES (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000071534-A1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LABORATORIES (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0973777-A1 | FUROPYRIDINE, THIENOPYRIDINE, PYRROLOPYRIDINE AND RELATED PYRIMIDINE, PYRIDAZINE AND TRIAZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998046609-A1 | FUROPYRIDINE, THIENOPYRIDINE, PYRROLOPYRIDINE AND RELATED PYRIMIDINE, PYRIDAZINE AND TRIAZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | DYRK1A 3207/4885HTT 33/4885KMT2A 1825/4885 |
| US-20230192617-A1 | AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS | TPMT, TST, NANP | DYRK1A 3940/4885HTT 1734/4885KMT2A 886/4885 |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | GRIN3A, GAP43, GRIN3B | DYRK1A 3093/4885HTT 2273/4885KMT2A 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.